CD11b Cancer Research Results

CD11b, CD11b: Click to Expand ⟱
Source:
Type:
CD11b’s (also known as integrin αM or ITGAM).
Markers CD14 and CD11b is one of the important characteristics of differentiation.

High levels of CD11b are often noted in the tumor microenvironment.
A high density of CD11b⁺ cells in the tumor microenvironment has been associated with adverse prognosis. For example, an abundance of MDSCs (which are CD11b⁺) is linked to immunosuppression, tumor progression, and resistance to therapies. High levels of CD11b⁺ cell infiltration have been correlated with:
-Faster tumor progression.
-Increased metastasis.
-Reduced response to immunotherapies.
Scientific Papers found: Click to Expand⟱
7183- CHA,    The SUV39H1 inhibitor chaetocin induces differentiation and shows synergistic cytotoxicity with other epigenetic drugs in acute myeloid leukemia cells
- in-vitro, AML, HL-60 - in-vitro, AML, KG-1 - in-vitro, lymphoma, U937
TumCD↓, The SUV39H1 inhibitor (chaetocin) and the G9a inhibitor (UNC0638) caused cell death in AML cells at high concentrations.
SUV39H↓,
CD11b↑, only chaetocin-induced CD11b expression and differentiation of AML cells at non-cytotoxic concentration.
Diff↑,
H3K9↓, Long-term incubation of chaetocin led to downregulation of SUV39H1 and reduction of H3K9 tri-methylation in HL-60 and KG-1a cells.
eff↑, Combination of chaetocin with suberoylanilide hydroxamic acid (SAHA, a histone deacetylase inhibitor) or JQ (a BET (bromodomain extra terminal) bromodomain inhibitor) showed synergistic cytotoxicity.

7011- Fuc,  ATO,  VitA,RetA,    Fucoidan enhances the therapeutic potential of arsenic trioxide and all-trans retinoic acid in acute promyelocytic leukemia, in vitro and in vivo
- NA, APL, APL NB4 - vitro+vivo, NA, NA
TumCCA↑, ATO and ATRA at therapeutic and sub-therapeutic doses, there was an increase in sub-G0/G1 cells, annexin V/PI-positive-apoptotic cells and DNA fragmentation.
DNAdam↑,
TumCP↓, this reduction in proliferation and increase in apoptosis was accompanied by enhanced myeloid differentiation as indicated by an increased expression of CD11b.
Apoptosis↑,
Diff↑,
CD11b↑,
eff↑, Fucoidan synergizes ATO-mediated apoptosis in APL cells
Dose↝, Decreased proliferation was observed at both low (0.25, 0.5 μM) and clinical doses of ATO (1 μM).

1345- SK,    The Critical Role of Redox Homeostasis in Shikonin-Induced HL-60 Cell Differentiation via Unique Modulation of the Nrf2/ARE Pathway
- in-vitro, AML, HL-60
CD14↑,
CD11b↑,
ROS↑, Shikonin result in the predominance of cell death because the oxidative stress is more severe and overcome the antioxidative capacity of Nrf2/ARE pathway, resulting in cell death.
GSH↓,
GSH/GSSG↓,
GPx↑, mRNA expression levels of GPX and CAT were markedly upregulated by Shikonin in a dose-dependent manner
Catalase↓, Shikonin causes apoptosis in human glioma cells by interrupting intracellular redox homeostasis, which included CAT downregulation
Diff↑, Shikonin-induced HL-60 cell differentiation


Showing Research Papers: 1 to 3 of 3

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 3

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

H3K9↓, 1,   SUV39H↓, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

Catalase↓, 1,   GPx↑, 1,   GSH↓, 1,   GSH/GSSG↓, 1,   ROS↑, 1,  

Cell Death(tgid=5) ⓘ

Apoptosis↑, 1,   TumCD↓, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

TumCCA↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

Diff↑, 3,  

Migration(tgid=13) ⓘ

CD11b↑, 3,   TumCP↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CD14↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

Dose↝, 1,   eff↑, 2,  
Total Targets: 17

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: CD11b, CD11b
1 chaetocin
1 Fucoidan
1 Arsenic trioxide
1 Vitamin A, Retinoic Acid
1 Shikonin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:1067  State#:%  Dir#:2
  wNotes=on  sortOrder:rid,rpid

 

Home Page